Indefinite Delivery Contract 75D30120D07116
Award Date
12/17/19
Last Date to Order
2/28/21
Federal Agency
CDC Pittsburgh
Awardee
Seqirus USA Inc.
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $253,319,000 multiple-award IDC has a period of performance from December 31, 2024 to February 28, 2026 and is intended to provide adult flu vaccines to support the CDC's annual immunization programs. Seqirus, through its Seqirus USA, Inc. division, is a...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc. to provide pediatric and adult influenza vaccines for the 2022-2023 season. The contract has a total ceiling value of $381,759,818.50 and covers the period from January 3, 2019 to February 28, 2019. Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery, will serve as the prime contractor on this multiple award IDC to...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $410,587,500 multiple-award IDC covers the procurement of 2025-2026 pediatric flu vaccines for the federal government. As a registered federal contractor since 2008, Seqirus USA Inc. has extensive experience supplying influenza vaccines to various government...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $143,324,800 contract is for the procurement of adult influenza vaccines for the 2022-2023 flu season, with a period of performance from the award date of December 31, 2021 through February 28, 2023. The contract does not utilize any set-asides and was awarded...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services, to Seqirus USA Inc. The contract has a ceiling value of $27,015,000 and is for the delivery of adult influenza vaccines for the 2019-2020 flu season. Seqirus USA Inc., through its Seqirus USA, Inc. division, is a global biotechnology company specializing in the development, manufacturing, and delivery of influenza...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the U.S. Department of Health and Human Services, to Seqirus USA Inc. through its Seqirus Usa, Inc. division. The contract has a ceiling value of $167,880,000 and is for the delivery of seasonal influenza vaccines during the 2018-2019 flu season. Seqirus is a global biotechnology company specializing in the development, manufacturing, and delivery of influenza...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency's Medical Supply Chain unit to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery. The contract, valued at $36,120,112.50, aims to procure approximately 3.23 million doses of injectable influenza virus vaccines in multi-dose vials and pre-filled syringes for various age groups, including elderly, adult, and pediatric populations. The vaccines are intended...
The Centers for Disease Control and Prevention awarded Seqirus USA Inc. a multiple award indefinite delivery contract with a potential value of $129.8 million to supply pediatric influenza vaccines through February 2028. Task orders will be issued against the contract to procure required vaccines annually to support the CDC's national immunization programs. As a leading manufacturer of influenza vaccines, Seqirus will deliver various formulations of pediatric flu vaccines to the CDC for...
This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency Troop Support Medical to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $27.5M IDC, which has a period of performance through June 2019, aims to procure approximately 3.6 million doses of injectable influenza vaccine in multi-dose vials and pre-filled syringes for various ages, including pediatric formulations. The contract supports...
The provided information describes an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in the development, manufacturing, and delivery of influenza vaccines. The $318,010,000 IDC, with a period of performance from January 2, 2024 to February 28, 2025, is for the procurement of pediatric flu vaccines to support the CDC's annual vaccination program. Seqirus, through its Seqirus USA,...